Suchergebnisse - "Mah, Jean K"

PubPharm (17)

1

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Neurology | 2024

von Mercuri, E. | Vilchez, J. | Boespflug-Tanguy, O. | +25

ErratumIn: Lancet Neurol. 2024 Apr 18;:. - PMID 38643778

2

Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy : A Randomized Controlled Trial

enthalten in: Neurology | 2024

von Dang, U. | Damsker, J. | Guglieri, M. | +41

3

Understanding the experiences of lung volume recruitment among boys with Duchenne muscular dystrophy : A multicenter qualitative study

enthalten in: Pediatric pulmonology | 2023

von Katz, S. | Blinder, H. | Newhook, D. | +10

4

Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy

enthalten in: Scientific reports | 2022

von Sherlock, S. | Palmer, J. | Wagner, K. | +8

5

Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy : A Randomized Clinical Trial

enthalten in: JAMA neurology | 2022

von Guglieri, M. | Clemens, P. | Perlman, S. | +43

6

Routine lung volume recruitment in boys with Duchenne muscular dystrophy : a randomised clinical trial

enthalten in: Thorax | 2022

von Katz, S. | Mah, J. | McMillan, H. | +16

CommentIn: Thorax. 2022 Aug;77(8):743-744. - PMID 35470244

7

Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy : a phase 2 trial of domagrozumab

enthalten in: Journal of neurology | 2022

von Sherlock, S. | Palmer, J. | Wagner, K. | +13

8

Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy : A Randomized Clinical Trial

enthalten in: JAMA | 2022

von Guglieri, M. | Bushby, K. | McDermott, M. | +61

9

Reldesemtiv in Patients with Spinal Muscular Atrophy : a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

ErratumIn: Neurotherapeutics. 2021 Jul;18(3):2130. - PMID 34731415

10

Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping : A Phase 2 Randomized Clinical Trial

enthalten in: JAMA neurology | 2020

von Clemens, P. | Rao, V. | Connolly, A. | +11

ErratumIn: JAMA Neurol. 2020 Aug 1;77(8):1040. - PMID 32539096